NCT00215150

Geodon for the Treatment of Refractory Social Anxiety Disorder

Ziprasidone for the Treatment of Refractory Social Anxiety Disorder

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 51 (actual)
• Sponsor: Duke University · Academic / Other
• Sex: All
• Age: 18 Years – 65 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this study is to examine the effectiveness and tolerability of augmentation treatment of ziprasidone to achieve remission among patients with social anxiety disorder (SAD) who did not remit on sertraline treatment alone

Detailed description

This is a two-phase study consisting of 8 weeks of open label treatment with sertraline (50-200 mg/day) in patients with SAD and in those who fail to demonstrate symptom remission on sertraline alone, 8 weeks of randomized, double-blind, placebo-controlled augmentation with ziprasidone.

Conditions

• Social Anxiety Disorder

Interventions

Type	Name	Description
DRUG	Ziprasidone	Sertraline augmentation with ziprasidone
DRUG	Sertraline	Treatment by sertraline in open label phase, followed by ziprasidone/placebo randomized augmentation in the randomized phase

Timeline

• Start date: 2004-11-01
• Primary completion: 2008-12-01
• Completion: 2009-07-01
• First posted: 2005-09-22
• Last updated: 2014-10-31
• Results posted: 2013-05-24

Locations

2 sites across 1 country: United States